4[1]DAVIS BM.Current progress in the gent therapy of cancer[J].Curr Opin Oncol,1996,8:499-508.
5[3]李树婷 .癌症疼痛的治疗 [M].北京 : 人民卫生出版社 , 1988:1-64.
6[4]王瑛译 .癌症疼痛治疗 [M].天津 : 天津科技翻译出版公司 , 1998:465.
7倪家骧.构筑治疗癌痛的第四阶梯.麻醉学论坛,1998,5(2):27-27.
8孙燕 顾慰萍.癌症三阶梯止痛指导原则[M].北京:北京医科大学出版社,2000.25-30.
9Zech D,Grond S,Dauer HG,et al.Transdermal fetanyl and initial does-finding with patient-con-trolled analgesia in cancer pain:a pilot study with 20 terminally ill cancer patients.Pain,1992,50:293～301.
10Ahmedzai S,Brooks D.Transdermal fentanyl versus sustained release orel morphine in cancer pain:preference,efficacy,and quality of life.J Pain Symptom,Manage,1997,13:254～261.
3Ashayeri E, Omogbehin A, Sridhar R, et al. Strontium 89 in the treatment of pain due to diffuse osseous metastases:a university hospital experience. J Natl Med Assoc, 2002, 94:706-711.
4中华人民共和国卫生部医政局.核医学诊断与治疗规范.北京:科学出版社,1997:292-295.
5Giammarile F, Mognetti T, Resche I. Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q J Nucl Mcd, 2001, 45: 78-83.
6Guanwardana DH, Lichtenstein M, Better N, et al. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med, 2004, 29: 81-85.
7Soerdjbalie-Maikoe V, Pelger RC, Lycklama a Nijeholt GA, et al. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging, 2002, 29: 494-498.
8Kraeber-Bode re F, Campion L, Rousseau C, et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride:efficacy in relation to the degree of bone involvement. Eur J Nucl Med, 2000, 27: 1487-1493.
